GlassScriptPhysician profile
Kevin Richardson
NPI 1689136897
$2,353.77
in general payments reported to CMS, 2019-2025
21 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $264 · 2023: $736 · 2024: $1,106 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,089.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $355.89 | 2022-2025 | Repatha, Otezla, Repatha |
| Mylan Specialty L.P. | $285.36 | 2023-2024 | Yupelri |
| Lilly USA, LLC | $264.65 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $253.69 | 2022-2025 | |
| Novo Nordisk INC | $191.74 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $186.46 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $172.09 | 2022-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.31 | 2023-2024 | Jardiance |
| Astellas Pharma US INC | $92.15 | 2022-2024 | Veozah |
| Glaxosmithkline, LLC. | $89.57 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $78.48 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.65 | 2023-2024 | Trintellix |
| Ironwood Pharmaceuticals, INC | $46.43 | 2023-2024 | Linzess |
| Axsome Therapeutics, INC. | $37.42 | 2024-2025 | Auvelity |
| Echosens North America, INC. | $32.15 | 2024 | Fibroscan |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $25.69 | 2024 | Zio Xt Patch |
| Phathom Pharmaceuticals, INC. | $23.58 | 2025 | Voquezna |
| Viatris Specialty LLC | $17.62 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $13.94 | 2022 | |
| Evoke Pharma, INC. | $13.48 | 2023 | Gimoti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.